The National Association of Healthcare Revenue Integrity Professionals (NAHRI) is currently accepting applications for its Advisory Board. Taking an active role in NAHRI can set you on the path to shape the future of the revenue integrity profession as well as advance your career. Applications are open to current or future NAHRI members and have been extended through March 9, 2020.
Planning is underway for the Fifth Annual Revenue Integrity Symposium, and this is one event you won’t want to miss taking an active role in. This year, we gather October 6–7, 2020, in Westminster (Denver), Colorado. RIS is NAHRI’s national conference—your chance to gather with likeminded professionals from across the country to make lasting connections while learning the latest strategies to excel in your career. And what better way to showcase your passion for revenue integrity and your ever-evolving skillset than getting up on stage and presenting to an audience of your peers.
Q: I'm told, although I'm not convinced, that our payment for Keytruda is denied by Anthem when we use Z51.11 (encounter for antineoplastic chemotherapy) first followed by the code for cancer, i.e. C34.12 (malignant neoplasm of upper lobe, left bronchus or lung). I reviewed the coding guidelines again and that is our instruction. Does anyone have experience with this issue?
